**DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN**

Division of Medicaid Services Wis. Admin. Code § DHS 107.10(2)

F-00081 (01/2024)

**FORWARDHEALTH**

**PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL)   
FOR OPIOID DEPENDENCY AGENTS – BUPRENORPHINE**

**INSTRUCTIONS:** Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Opioid Dependency Agents–Buprenorphine Instructions, F-00081A. Prescribers may refer to the Forms page of the ForwardHealth Portal at [www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/  
ForwardHealthCommunications.aspx?panel=Forms](https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ForwardHealthCommunications.aspx?panel=Forms)for the completion instructions.

Pharmacy providers are required to have a completed PA/PDL for Opioid Dependency Agents–Buprenorphine form signed and dated by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal, by fax, or by mail. Prescribers and pharmacy providers may call Provider Services at 800-947-9627 with questions.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **SECTION I – MEMBER INFORMATION** | | | | | |
| 1. Name – Member (Last, First, Middle Initial) | | | | | |
| 2. Member ID Number | | 3. Date of Birth – Member | | | |
| **SECTION II – PRESCRIPTION INFORMATION** | | | | | |
| 4. Drug Name | | 5. Drug Strength | | | |
| 6. Date Prescription Written | | 7. Refills | | | |
| 8. Directions for Use | | | | | |
| 9. Name – Prescriber | | | | | |
| 10. Address – Prescriber (Street, City, State, Zip+4 Code) | | | | | |
| 11. Phone Number – Prescriber | | | 12. National Provider Identifier (NPI) – Prescriber | | |
| **SECTION III – CLINICAL INFORMATION (Required for All PA Requests)** | | | | | |
| 13. Diagnosis Code and Description | | | | | |
| 14. Is the member 16 years of age or older?  Yes  No | | | | | |
| 15. Is the member taking any other opioids, tramadol, or carisoprodol?  Yes  No  If yes, list the drugs taken and the dates they have been taken in the space provided. | | | | | |
| 16. Is the member pregnant?  Yes  No  If yes, indicate the member’s expected delivery date (mm/dd/ccyy).        /       / | | | | | |
| **SECTION IV – ADDITIONAL CLINICAL INFORMATION FOR NON-PREFERRED BUPRENORPHINE-NALOXONE DRUG REQUESTS (PA requests for non-preferred buprenorphine-naloxone drugs may not be submitted via STAT-PA.)** | | | | | |
| 17. Provide detailed clinical justification for prescribing a non-preferred buprenorphine-naloxone drug instead of buprenorphine-naloxone tablets, Suboxone film, and Zubsolv. Include clinical information why the member cannot use buprenorphine-naloxone tablets, Suboxone film, and Zubsolv and why it is medically necessary that the member receive a non-preferred buprenorphine-naloxone drug instead of buprenorphine-naloxone tablets, Suboxone film, and Zubsolv. | | | | | |
| **SECTION V – ADDITIONAL CLINICAL INFORMATION FOR BRIXADI REQUESTS (PA requests for Brixadi may not be submitted via STAT-PA.)** | | | | | |
| 18. Provide detailed clinical justification for prescribing Brixadi instead of Sublocade, including clinical information why the member cannot use Sublocade and why it is medically necessary that the member receive Brixadi instead of Sublocade. | | | | | |
| **SECTION VI – AUTHORIZED SIGNATURE** | | | | | |
| 19. **SIGNATURE** – Prescriber | | | | | 20. Date Signed |
| **SECTION VII – FOR PHARMACY PROVIDERS USING STAT-PA** | | | | | |
| 21. National Drug Code (11 Digits) | | 22. Days’ Supply Requested (Up to 183 Days) | | | |
| 23. NPI | | | | | |
| 24. Date of Service (DOS) (mm/dd/ccyy) (For STAT-PA requests, the DOS may be up to 31 days in the future or up to 14 days in the past.) | | | | | |
| 25. Place of Service | | | | | |
| 26. Assigned PA Number | | | | | |
| 27. Grant Date | 28. Expiration Date | | | 29. Number of Days Approved | |
| **SECTION VIII – ADDITIONAL INFORMATION** | | | | | |
| 30. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may be included here. | | | | | |